1339617705763217409

Today we completed a public offering of ordinary shares that totaled $65 million and is designed to enable us to bring omidubicel closer to patients and advance our natural killer cell therapy, GDA-201. #celltherapy #InspiredToCure More here: https://t.co/ePsreZ7nto https://t.co/BlpdGrwXPb

Send us a message